Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016393 · ClinicalTrials.gov registry record · Phase 2
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00016393: Completed Phase 2 study, sponsored by SWOG Cancer Research Network.
NCT00016393 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016393, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have prostate cancer that has not responded to hormone therapy.
Interventions
- DRUG ixabepilone
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
What the finished NCT00016393 record still lists
NCT00016393 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ixabepilone is the first listed.
NCT00016393 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00016393 about?
NCT00016393 is a clinical study titled "BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have prostate cancer that has not responded to hormone therapy.
What is the current status of trial NCT00016393?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-06. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00016393?
The interventions under investigation include: ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00016393?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia